Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92885Research ArticleAgonisty dofaminovykh retseptorov – preparaty vybora terapii rannikh stadiy bolezni ParkinsonaFedorovaN. V-151220081012556128122021Copyright © 2008, Consilium Medicum2008[Артемьев Д.В., Обухова А.В. Современные подходы к лечению ранних стадий болезни Паркинсона. Consilium Medicum 2008; 10 (7): 89–92.][Левин О.С. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Леч. нервн. бол. 2003; 4 (1): 14–7.][Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврол. журн. 1999; 6 (4): 45–9.][Федорова Н.В., Кулуа Т.К. Опыт применения прамипексола в лечении болезни Паркинсона. Consilium Medicum 2007; 9 (2): 103–7.][Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсона. Рус. мед. журн. 2000; 8 (15): 643–7.][Chaudhuri K.R, Healy D.G, Schapira A.H. National Institute for Clinical Exellene. Non - motor symptoms of Parkinson\'s disease: diagnosis and management. Lancet Neurol 2006; 5: 235–45.][Corrigan M.H, Denahan A.Q, Wright C.E, Ragual R.J. Comparison of pramipexole, fluoxetini, and placebo in patients with major depression. Depress. Anxiety 2000; 11: 58–65.][Fhan S, Oakes O, Shoulson I et al. Levodopa and progression of Parkinson\'s disease. N. Engl J Med 2004; 351: 2498–508.][Goetz C.G. Dopaminergic agonists in the treatment of Parkinson\'s disease. Neurology 1990; 40 (Suppl. 3): 50–4.][Goetz C.G, Blasucci L, Stebbins G.T. Switching dopamine agonists in advanced Parkinson\'s disease. Is rapid titration preferable to slow? Neurology 1999; 52: 1227–9.][Goldberg J.F, Frye M.A, Dunn R.T. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999; 156: 798.][Hauzer R, Reider C, Stacey M et al. Acute versus gradual pramipexole to ropinirile switch. Mov Disord 2000; 15 (Suppl. 3): 133.][Holloway R.G, Shoulson I, Kieburts K et al. Pramipexole vs. levodopa as initial treatment for Parkinson\'s disease – a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044–53.][Jenner P. The MPTP - treated primate as a model of motor complications. Neurology 2003; 61 (Suppl. 3): 4–11.][Junghanns S, Glockler T, Reichmann H. Switching and combing of dopamine agonists. J Neurol 2004; 251 (Suppl. 6): 19–23.][Junghanns S., Glockler T., Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 251 (Suppl. 6): 19–23.][King D.F, Cooper J.M, Schapira A.H. Pramipexole protects against MPP+toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 2001; 56: 377–88.][Lang A.E. Are the new dopamine agonists better than the old ones? 6th International congress of Parkinson\'s disease and movement disorders Barcelona, Spain, 2000.][Lemke M.R, Brecht H.M, Koester J еt al. Anhgedonia, depression, and motor functioning in Parkinson\'s disease during treatment with pramipexole. J Neurops Clin Neurosc 2005; 17: 214–20.][Lev N, Dialdetti R, Melamed E. Initiation of symptomatic therapy in Parkinson\'s disease: dopamine agonists vs. levodopa. J Neurol 2007; 254 (suppl. 5): 19–26.][Linazasoro G. Conversion from dopamine agonists to pramipexole. J Neurol 2004; 251: 335–9.][Molho E.S, Factor S.A, Weiner W.J et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson\'s disease. J Neural Transm 1995; 45 (Suppl): 225–30.][Navan P, Findley L.J, Pearce R.G et al. A randomly assigned double - blind cross - over study examining the relative anti - parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005; 12 (1): 1–8.][Noyes K, Dick A, Holloway R.G. and the Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson\'s disease. A randomized clinical - economic trail. Med Decis Making 2004; 24: 472–85.][Oertel W.H. Pergolide vs Levodopa (PELMOPET). Mov Disord 2000; 15 (Suppl. 3): 86.][Oertel W.H, Wolters E, Sampaio C еt al. Pergolide vs. levodopa monotherapy in early Parkinson\'s disease patients: PELMOPET study. Mov Disord 2006; 21: 343–53.][Olanov C.W, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson\'s disease:current controversies. Mov Disord 2004; 19: 997–1005.][Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson\'s disease:A randomized controlled trial. JAMA 2000; 284: 1931–8.][Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson\'s disease: design and methods of the CALM-PD study. J Clin Neuropharmakol 2000; 23 (1): 34–44.][Pogarell O, Gasser T, Hilten J et al. Pramipexole in patients with Parkinson\'s disease and marked drug resistant tremor: a randomized, double - blind study, placebo controlled multicenter study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20.][Pogarell O, Gasser T, van Hilten J et al. Pramipexole in patients with Parkinson\'s disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20.][Rajput A.H. Adverse effects of ergot - derivative dopamine agonists. Eds: C.Olanow, J.Obeso. Dopamine agonists in early Parkinson\'s disease. Kent, – UK: Wells Medical 1997; 209–16.][Rascol O, Brooks D.J, De Deyn P et al. Five - year study of the incidence of dyskinesia in patients with early Parkinson\'s disease who were treated with ropinirole or levodopa. N Engl Med 2000; 342: 1484–91.][Rascol O, Rayoux P, Ferreira J et al. The management of patients with early Parkinson\'s didease. Parkinonism Relat Disord 2002; 9: 61–7.][Reichmann H, Odin P, Brecht H.M et al. Changing dopamine agonist treatment in Parkinson\'s disease: experience with switching to pramipexole. J Neural Transm 2006; 71 (Suppl.): 17–25.][Samii A, Nutt J.G, Ranson B.R. Parkinson\'s disease. Lancet 2004; 363: 1783–94.][Schapira A.H. Neuroprotection and dopamine agonists. Neurology; 58 (Suppl. 1): 9–18.][Schapira A.H, Hsu H.H, Scrine K et al. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson\'s disease. Mov Disor 2008; 23 (Supp. 1): 194.][Schapira A.H, Obeso J. Timing of treatment initiation in Parkinson\' disease: a need for reappraisal? Ann Neurol 2006; 59: 562–4.][Stocchi F, Berardelli A, Vacca L et al. Combination of two different dopamine agonists in the management of Parkinson\'s disease. Neurol Sci 2002; 23 (Suppl. 2): 115–6.][Takahashi H, Nogawa S, Tachibana J et al. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. J Int Med Res 2008; 36 (1): 106–14.][Tatton W.G, Ju W.Y.H, Wadia J et al. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. Eds. C.Olanov, P.Jenner, M.Youim. Neurodegeneration and neuroprotection in Parkinson\'s disease. London: Academic Press 1996; 202–20.][Thomas A, Bonanni L, Di Lorio A et al. End - of - dose deterioration in non ergolinic dopamine agonist monoterapy of Parkinson\'s disease. J Neurol 2006; 253: 1633–9.][Uitti R.J, Ahlskog J.E. Comparative review of dopamine receptor agonists in Parkinson\'s disease. Drugs 1996; 5: 369–88.][Wolters E.C, Tissingh G, Bergmans P.L.M et al. Dopamine agonists in Parkinson\'s disease. Neurology. 1995; 45 (Suppl. 3): 28–34.]